A MULTICRITERIA DECISION ANALYSIS (MCDA) TO EVALUATE ALTERNATIVE TREATMENTS FOR LOCALLY ADVANCED OR METASTATIC EGFR POSITIVE NON-SMALL CELL LUNG CANCER UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Teich, V [1 ]
Custodio, M. G. [2 ]
Laloni, M. T. [3 ]
Costa, M. A. D. S. B. [4 ]
Campolina, A. G. [5 ]
Holtz, L. [6 ]
Oliveira, M. [7 ]
Bortoleto, N. [8 ]
Salgado, J. [9 ]
机构：
[1] Sense Co, Sao Paulo, Brazil
[2] AstraZeneca, Cotia, Brazil
[3] Ctr Paulista Oncol, Sao Paulo, SP, Brazil
[4] Oswaldo Cruz Hosp, Sao Paulo, Brazil
[5] Univ Sao Paulo, Sao Paulo, Brazil
[6] Oncoguia, Sao Paulo, Brazil
[7] Inst Lado & Lado Pela Vida, Sao Paulo, Brazil
[8] Abrale, Sao Paulo, Brazil
[9] AstraZeneca Brasil, Cotia, Brazil
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.343
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN221
引用
收藏
页码：S98 / S98
页数：1
相关论文
共 50 条
  • [1] A MULTICRITERIA DECISION ANALYSIS (MCDA) TO EVALUATE ALTERNATIVE TREATMENTS FOR SEVERE ASTHMA IN ADULT PATIENTS UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Teich, V
    Penha, M. F.
    Sano, F.
    San Martin, G.
    Farina, T.
    Gondo, C.
    Campolina, A. G.
    Mattar, Z. D. L.
    Salgado, J.
    VALUE IN HEALTH, 2019, 22 : S358 - S358
  • [2] A MULTICRITERIA DECISION ANALYSIS (MCDA) TO EVALUATE ALTERNATIVE MAINTENANCE STRATEGIES FOR TREATMENT OF RECENTLY DIAGNOSED ADVANCED OVARIAN CANCER (AOC) WITH BRCA MUTATION UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Teich, V
    Rodrigues, A. N.
    de Freitas, D.
    Gadelha, A. P.
    Oliveira, M.
    Holtz, L.
    Battistini, C. J.
    Santi, A.
    Pombo, F. H.
    Santos, M. C. L.
    Monteiro, I. P.
    Mensor, L.
    VALUE IN HEALTH, 2019, 22 : S506 - S506
  • [3] PREVENTING BRAIN METASTASES WITH ALECTINIB IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER: ECONOMIC IMPACT UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Kashiura, D.
    Santos, M.
    Carmo, L.
    Leme-Souza, R.
    VALUE IN HEALTH, 2019, 22 : S80 - S80
  • [4] CrizotinibIn Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Monique P. Curran
    Drugs, 2012, 72 (1) : 99 - 107
  • [5] Crizotinib In Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Curran, Monique P.
    DRUGS, 2012, 72 (01) : 99 - 107
  • [6] COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Stefani, S. D.
    Santos, M.
    Kashiura, D.
    Leme-Souza, R.
    Fahham, L.
    VALUE IN HEALTH, 2019, 22 : S478 - S479
  • [7] Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer
    Higgins, Jordyn P.
    Carlisle, Jennifer W.
    Moniri, Nader H.
    Gupta, Shruti
    Oduah, Eziafa I.
    Leal, Ticiana
    FUTURE ONCOLOGY, 2025, 21 (01) : 63 - 71
  • [8] Treatment of locally advanced and metastatic non-small cell lung cancer in the elderly
    Zimmermann, FB
    Molls, M
    Jeremic, B
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (01) : 203 - +
  • [9] Afatinib in EGFR mutation positive advanced non-small cell lung cancer
    Davies, R. S.
    Brewster, A. E.
    Button, M. R.
    Lester, J. F.
    LUNG CANCER, 2016, 91 : S22 - S22
  • [10] Comparison of the efficacy of two treatments in locally advanced non-small cell lung cancer
    Cui Youbin
    Liu Guangming
    Zhang Jie
    Zhou Da
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S829 - S829
12345